Pyrimidine derivatives as PIM kinase inhibitors and preparation methods and use in medicinal manufacture thereof

ABSTRACT

PIM kinase inhibitor compound having a structure as represented by Formula I, and isomers, diastereomers, enantiomers, tautomers, and pharmaceutically acceptable salts thereof. The compounds significantly inhibit the Pim kinase activity and are used to prepare drugs to treat PIM kinase mediated diseases, such as cancers, multi drug resistance, and inflammatory bowel disease. Also provided are methods for preparing and using the compounds represented by Formula I.

CROSS-REFERENCE AND RELATED APPLICATIONS

The subject application is a continuation-in-part of U.S. patent application Ser. No. 14/177,156 filed on Feb. 10, 2014, now allowed, which is a continuation of PCT international application PCT/CN2012/001060 filed on Aug. 8, 2012, which in turn claims priority on Chinese patent applications CN 201110229731.X filed on Aug. 11, 2011 and CN 201210271738.2 filed on Aug. 1, 2012. The contents and subject matters of all the priority applications are incorporated herein by reference.

TECHNICAL FIELD

The present invention relates to medicinal chemistry, particularly, PIM kinase inhibitors, methods of preparation, and their pharmaceutical application in treating diseases.

BACKGROUND

PIM kinase family consists of three homologous serine/threonine kinases, Pim-1, Pim-2, and Pim-3, which belongs to calmodulin-dependent protein kinase-related family (CAMK). Researchers have shown that PIM kinases are widely expressed in hematopoietic tissues (J. Biol. Chem., 280, 14168-14176, 2005; Blood, 105, 4477-4483, 2005) and play important roles in cell survival and proliferation. Since PIM kinases are overexpressed in a variety of malignancies and inflammations (J. Exp. Med., 201, 259-266, 2005; Biochem. Soc. Trans., 32, 315-319, 2004), they are more and more being targeted for treating cancers and immune dysfunctions. PIM-1 (Provirus Integration of Maloney 1) is originally identified in a series of insertional mutagenesis studies of retroviruses, as a frequent proviral integration site in Moloney murine leukemia virus-induced T-cell lymphomas, and PIM-1 is named based on that finding (Cell, 37, 141-150, 1984). It is found later that the genes encoding PIM-2 (Provirus Integration of Maloney 2) have the same defect (J. Clin. Invest., 115, 2679-2688, 2005). Pim-2 has similar effects as and compensatory to Pim-1 (J EMBO, 14, 2536, 1995). PIM-3 is initially named as KID-1 (Kinase Induced by Depolarization 1), but renamed to Pim-3 because of its high sequence similarity to Pim-1 (Nature, 428, 332-337, 2005; Cell, 56, 673-682, 1989). PIM-1, 2, 3 are overly expressed in many hematopoietic malignancies (Proc. Natl. Acad. Sci. U.S.A., 86, 8857-8861, 1989). PIM-1 is found to be overexpressed in the development of prostate cancer (J. Clin. Pathol., 59, 285-288, 2006). PIM-2 expression is elevated in human chronic lymphocytic leukemia and non-Hodgkin's lymphoma leukemia (Leuk. Lymph., 45, 951-955, 2004), the aberrant expression of PIM-3 is believed to have played an important role in the development and proliferation of liver fibroma (Int. J. Cancer, 114, 209-218, 2005) and pancreatic cancer (Cancer Res., 66, 6741-6747, 2006).

PIM-1, PIM-2, and PIM-3 have effects on the survival and proliferation of hematopoietic cells in response to growth factors stimulation. PIM-1, 2, 3 triple knockout mice are viable and fertile while displaying reduced body size and impairment of proliferation of hematopoietic cells in response to growth factors. Knocking out one of 3 kinases does not have obvious effect on mice, indicating some overlapping functions among PIM kinases (Cell, 56, 673-682, 1989). The substrates of PIM kinases include Bcl-2 family members such as pro-apoptotic BAD protein (FEBS Letters, 571, 43-49, 2004), cell cycle regulating p21 (Biochem. Biophys. Acta, 1593, 45-55, 2002), CDC25A, C-TA (J. Biol. Chem., 279, 48319-48328, 2004), protein synthesis related 4EBP1 (Blood, 105, 4477-4483, 2005). These functions of PIM kinases indicate that PIM kinases can prevent apoptosis and promote cell growth and proliferation. Their overexpression in cancer cells promotes the survival and proliferation of the cancer cells. Therefore, inhibiting the PIM kinase activities in cancer cell is a new effective way of treating cancers.

Based on the evidence that PIM kinases are involved in hematological cancers and solid tumors, a number of PIM inhibitors have been developed to treat a variety of cancers. It is shown in a series of cellular assays and in vivo models that PIM inhibitors can significantly inhibit Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic myelogenous leukemia (CML), Non-Hodgkin's Lymphoma (NHL), and Multiple Myeloma (MM) cell proliferation and tumor growth in xenograft model (Clin. Cancer Res. 20(7), 1834-1845, 2014; Blood 123(6), 905-913, 2014; Blood 122(21), 4435, 2013). It has also been demonstrated that PIM inhibitors are useful to treat PIM overexpressed solid tumors such as pancreatic cancers (Cancer Biol. Ther. 7(9), 1352-9, 2008 Cancer Res. 2006; 66(13):6741-7; Cancer Res. 70(24), 10288-10298, 2010), prostate cancers (Prostate, 65(3), 276-86, 2005; Prostate, 73(13), 1462-1469, 2013), liver cancers (J. Surg. Res., 153(1), 17-22, 2009; Int. J. Cancer, 114(2), 209-18, 2005), gastric cancer (J. Cancer Res. Clin. Oncol., 134(4), 481-8, 2008), and bladder cancer (J. Exp. Clin. Cancer Res., 29, 161, 2010).

Moreover, resistance to chemotherapeutics and molecularly targeted drugs is a major obstacle in cancer treatment (Drug Resistance Updat. 12, 114-126. 2009). It has also been reported that PIM kinases are involved in the expression and activity of MDR-1 and BCRP, two of the most important drug efflux transporters. “It is abundantly clear from the preclinical models that PIM inhibition can significantly reverse drug resistant phenotypes.” See Drug Resistance Updates, 14, 203-211, 2011. It has been demonstrated that the use of PIM inhibitors in combination with chemotherapeutics can significantly increase their potencies against drug resistant prostate cancer (Mol. Cancer Ther. 8, 2882-2893, 2009). Therefore, PIM kinase inhibitors are used to reverse the multi drug resistance.

Further, PIM kinases are expressed following T cell activation. Studies show that therapeutic dosing of a PIM-1/3 inhibitor is efficacious in a CD4+ T cell-mediated model of inflammatory bowel disease. Oral administration of AR452530 significantly decreases colon inflammation, gland loss, edema, and mucosal thickness by at least 80%. Therefore, PIM-1/3 kinases have an important role in CD4+ T cell responses and inhibition of this activity may provide a therapeutic benefit in T cell-mediated diseases. See Cellular Immunology, 272, 200-213, 2012.

SUMMARY OF THE INVENTION

The present invention provides chemical compounds having certain biological activities that include, but not limited to, inhibiting cell proliferation, promoting apoptosis, and modulating protein kinase activities. The present invention provides compounds that inhibit the activities of PIM-1, PIM-2 and PIM-3 kinases. The present invention also provides methods for preparing the novel chemical compounds and analogs thereof, and methods of using these compounds to treat cancers, autoimmune diseases, allergic reactions, and organ transplant rejection.

The PIM kinase inhibitors of the present invention have the following general structural Formula I, and their stereoisomers, tautomers, and pharmaceutically acceptable salts,

wherein Z₁ and Z₂ are independently selected from a CR₂, a CR₃, and a nitrogen (N), provided that Z₁ and Z₂ cannot be N at the same time;

R₁ is a hydrogen (H), —NHR₄, a halogen, a hydroxyl, an alkyl, a cyano, or a nitro group;

R₂ and R₃ are each independently selected from a hydrogen, —NHR₅, a halogen, a hydroxyl, a substituted or unsubstituted alkyl, an alkenyl, an alkynyl, an alkoxyl, a cycloalkyl, an amino, a cyano, and a nitro group;

R₄ is a hydrogen, —C(═O)—R₅, a substituted or unsubstituted alkyl, a cycloalkyl, a heterocyclyl, an aryl, or a heteroaryl;

R₅ is a substituted or unsubstituted alkyl, an alkenyl, an alkynyl, an alkoxyl, a cycloalkyl, an amino, or a substituted amino group;

R₆ is a substituted or unsubstituted aryl, a heteroaryl, a cycloalkyl, where each substituted R₆ group is substituted with up to four substituents that is a halogen, a cyano, an amino, a C₁₋₄ alkyl, a C₃₋₆ cycloalkyl, an alkoxyl, a nitro, a carboxy, a carbonyl, a carboalkoxy, or an aminocarboxy;

E is an OR₂₂, a SR₂₂, or a SO₂R₂₂; R₂₂ is an optionally substituted C₁-C₈ hydrocarbon group or a group described in the following formula:

wherein each of R₂₃, R₂₄, R₂₅ is independently selected from a H, a halogen, an OR₁₅, a NR₁₆R₁₇, a C(═O)N R₁₈R₁₉, or an optionally substituted C₁-C₈ hydrocarbon group; or R₂₃, R₂₄ and R₂₅, together with the atoms to which they are attached, may be joined together to form a chain so that the ring to which they are attached is a substituted C₆-C₁₄ membered spiral ring, a bicyclic ring, or a fused ring group;

G₁ is —CH or N;

G₂ is NR₂₈, CHR₂₉ or O;

B1 and B2 each independently represents 0, 1, 2, or 3;

B3 is 0, 1, or 2;

B4 is 0 or 1;

Each of R₁₆, R₁₇, R₁₈, R₁₉, R₂₆ and R₂₇ is independently selected from a H or an optionally substituted C₁-C₈ hydrocarbon group;

R₂₈ is H, an optionally substituted hydrocarbon group, an optionally substituted cyclic hydrocarbon group, an optionally substituted heterocyclic hydrocarbon group, a C(═O)R₃₀, C(═O)OR₃₀, or a C(═O)NHR₃₀;

R₂₉ is an OH, a NHR₃₀, a C(═O)OR₃₀, or a C(═O)NHR₃₀; and

R₃₀ is H or an optionally substituted C₁-C₈ hydrocarbon group.

In some embodiments of the present invention, the compounds of Formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof have Z₁ and Z₂ that are CR₂ and CR₃, respectively.

In some other embodiments of the present invention, the compounds of Formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof have R₂ and R₃ that are independently selected from a hydrogen, a methyl, an ethyl, a halogen, and a cyano group.

In yet another embodiments of the present invention, in the compounds of Formula I and their stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, Z₁ is CR₂, Z₂ is CR₃, and E is O—R₂₂, so that they have the following structure of formula II:

DETAILED DESCRIPTION OF THE INVENTION

The PIM kinase inhibitors of the present invention and their stereoisomers, tautomers, and pharmaceutically acceptable salts have the following general structural Formula I:

wherein Z₁ and Z₂ are independently selected from a CR₂, a CR₃, and a nitrogen (N), provided that Z₁ and Z₂ cannot be N at the same time;

R₁ is a hydrogen (H), —NHR₄, a halogen, a hydroxyl, an alkyl, a cyano, or a nitro group;

R₂ and R₃ are each independently selected from a hydrogen, —NHR₅, a halogen, a hydroxyl, a substituted or unsubstituted alkyl, an alkenyl, an alkynyl, an alkoxyl, a cycloalkyl, an amino, a cyano, and a nitro group;

R₄ is a hydrogen, —C(═O)—R₅, a substituted or unsubstituted alkyl, a cycloalkyl, a heterocyclyl, an aryl, or a heteroaryl;

R₅ is a substituted or unsubstituted alkyl, an alkenyl, an alkynyl, an alkoxyl, a cycloalkyl, an amino, or a substituted amino group;

R₆ is a substituted or unsubstituted aryl, a heteroaryl, a cycloalkyl, where each substituted R₆ group may be substituted with up to four substituents that is a halogen, a cyano, an amino, a C₁₋₄ alkyl, a C₃₋₆ cycloalkyl, an alkoxyl, a nitro, a carboxy, a carbonyl, a carboalkoxy, or an aminocarboxy;

E is an OR₂₂, a SR₂₂, or a SO₂R₂₂; R₂₂ is an optionally substituted C₁-C₈ hydrocarbon group or a group described in the following formula:

wherein each of R₂₃, R₂₄, R₂₅ is independently selected from a H, a halogen, an OR₁₅, a NR₁₆R₁₇, a C(═O)N R₁₈R₁₉, or an optionally substituted C₁-C₈ hydrocarbon group; or R₂₃, R₂₄ and R₂₅, together with the atoms to which they are attached, may be joined together to form a chain so that the ring to which they are attached is a substituted C₆-C₁₄ membered spiral ring, a bicyclic ring, or a fused ring group;

G₁ is —CH or N;

G₂ is NR₂₈, CHR₂₉ or O;

B1 and B2 each independently represents 0, 1, 2, or 3;

B3 is 0, 1, or 2;

B4 is 0 or 1;

Each of R₁₆, R₁₇, R₁₈, R₁₉, R₂₆ and R₂₇ is independently selected from a hydrogen (H) or an optionally substituted C₁-C₈ hydrocarbon group;

R₂₈ is H, an optionally substituted hydrocarbon group, an optionally substituted cyclic hydrocarbon group, an optionally substituted heterocyclic hydrocarbon group, a C(═O)R₃₀, C(═O)OR₃₀, or a C(═O)NHR₃₀;

R₂₉ is an OH, a NHR₃₀, a C(═O)OR₃₀, or a C(═O)NHR₃₀; and

R₃₀ is H or an optionally substituted C₁-C₈ hydrocarbon group.

In some embodiments of the present invention, the compounds of Formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof have Z₁ and Z₂ that are CR₂ and CR₃, respectively.

In some other embodiments of the present invention, the compounds of Formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof have R₂ and R₃ that are independently selected from a hydrogen, a methyl, an ethyl, a halogen, and a cyano group.

In yet another embodiments of the present invention, the compounds of Formula I and their stereoisomer, tautomer, or pharmaceutically acceptable salt thereof have the structure of formula I where Z₁ is CR₂, Z₂ is CR₃, and E is O—R₂₂, and the structure is described as the following formula II:

In some embodiments of the present invention, the compounds of Formula I or II, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof are provided where R₁ is a hydrogen, an amino or a fluoro. Preferred embodiments of the compounds of Formula II of the present invention are provided at the following Table I.

In some embodiments of the present invention, the compounds of Formula I or II, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof are provided where R₆ is a substituted or unsubstituted aryl, a hetero aryl, a C₄-C₆ cycloalkyl, a partially unsaturated C₄-C₆ cycloalkyl, where each group can be substituted with up to four substituents that is a halogen, a cyano, an amino, an alkyl, an alkoxy, a cycloalkyl, a nitro, a carboxyl, a carboalkoxy, an aminocarboxy, a substituted aminocarbonyl, an aminosulfonyl, a substituted aminosulfonyl, or an alkoxyalkyl.

In some embodiments of the present invention, the compounds of Formula I or II, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof are provided where R₆ is a substituted or unsubstituted phenyl, where the phenyl group can be substituted with up to three substituents that is a hydrogen, a cyano, a nitro, a halogen, a hydroxyl, an amino, an alkoxy, a substituted amino, an alkyl, a cycloalkyl. In some embodiments of the present invention, the compounds of Formula I or II or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof are provided where R₆ is 2,6-difluorophenyl.

In some embodiments of the present invention, the compounds of Formula I or II, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof are provided where R₂ and R₃ are each independently selected from a hydrogen, a halogen, a cyano, a methyl, or an ethyl.

In some embodiments of the present invention, the compounds of Formula I or II, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof are provided where R₂₂ is a substituted or unsubstituted cyclobutyl, a cyclopentyl, a cyclohexyl, a cycloheptyl, an azetidyl, a pyrrolidinyl, a piperidinyl, an azepanyl, an oxetyl, a tetrahydrofuryl, a tetrahydropyranyl, where the R₂₂ group may be substituted with up to three substitutents that is an amino, a hydroxy, a methyl, an ethyl, or a methoxy; R₁ is a hydrogen, an amino, or a fluoro; R₂ and R₃ are each independently selected from a hydrogen, a halogen, and a methyl; R₆ is a substituted or unsubstituted phenyl, where the phenyl group can be substituted with up to three substituents that is a hydrogen, a cyano, a nitro, a halogen, a hydroxyl, an amino, an alkoxy, a substituted amino, an alkyl, or a cycloalkyl.

In some embodiments of the present invention, the compounds of Formula I or II, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof are provided where R₂₂ is a substituted or unsubstituted cyclobutylmethyl, a cyclopentylmethyl, a cyclohexylmethyl, a cycloheptylmethyl, an azetidylmethyl, a pyrrolidinylmethyl, a piperidinylmethyl, an azepanylmethyl, an oxetylmethyl, a tetrahydrofurylmethyl, a tetrahydropyranylmethyl, where the R₂₂ group may be substituted with up to three substitutents that is an amino, a hydroxy, a methyl, an ethyl, or a methoxy; R₁ is a hydrogen or an amino; R₂ and R₃ are each independently selected from a hydrogen, a halogen, and a methyl; R₆ is a substituted or unsubstituted phenyl, where the phenyl group can be substituted with up to three substituents that is a hydrogen, a cyano, a nitro, a halogen, a hydroxyl, an amino, an alkoxy, a substituted amino, an alkyl, or a cycloalkyl.

A preferred embodiment of the present inventions is a compound of Formula II, where R₂₂ is a substituted or unsubstituted cyclohexyl, azetidyl, pyrrolidinyl, piperidinyl, azepanyl, tetrahydrofuryl, or tetrahydropyranyl group, and preferably a cyclohexyl, pyrrolidinyl, piperidinyl, or azepanyl group, where the R₂₂ group may be substituted with up to three substitutents that is an amino, a hydroxy, a methyl, an ethyl, or a methoxy group, and preferably an amino, a hydroxy, or a methyl group; R₁ is a hydrogen, an amino, or a fluoro; R₂ and R₃ are each independently selected from a hydrogen, a halogen, and a methyl, and preferably R₂ is a hydrogen and R₃ is a halogen; R₆ is a substituted or unsubstituted phenyl, where the phenyl group can be substituted with up to three substituents that is a hydrogen, a cyano, a nitro, a halogen, a hydroxyl, an amino, an alkoxy, a substituted amino, an alkyl, or a cycloalkyl, and preferably a hydrogen, a cyano, or a halogen, and most preferably a hydrogen or a halogen.

Yet another preferred embodiment of the present inventions is a compound of Formula II, where R₂₂ is a substituted or unsubstituted cyclohexylmethyl, azetidylmethyl, pyrrolidinylmethyl, piperidinylmethyl, azepanylmethyl, tetrahydrofurylmethyl, or tetrahydropyranylmethyl group, and preferably, a cyclohexylmethyl, pyrrolidinylmethyl, piperidinylmethyl, or azepanylmethyl group, where the R₂₂ group may be substituted with up to three substitutents that is an amino, hydroxy, methyl, ethyl, or methoxy, and preferable an amino, hydroxy, or methyl; R₁ is a hydrogen, an amino, or a fluoro; R₂ and R₃ are each independently selected from a hydrogen, a halogen, and methyl, and preferably R₂ is a hydrogen and R₃ is a halogen; R₆ is a substituted or unsubstituted phenyl, where the phenyl group can be substituted with up to three substituents that is a hydrogen, a cyano, a nitro, halogen, hydroxyl, an amino, an alkoxy, a substituted amino, an alkyl, or a cycloalkyl, and preferably a hydrogen, a cyano, or a halogen, and most preferably a hydrogen or a halogen.

Yet another preferred embodiment of the present inventions is a compound of Formula II, wherein R₂₂ is a substituted C₂-C₅ alkyl, the substituted R₂₂ group may be substituted at any position on the substituent with up to four substitutents that is an amino, an alkylamino, a hydroxy, a halogen, a methyl, an ethyl, a halogenated methyl, or a halogenated ethyl group; R₁ is a hydrogen, an amino, or a fluoro; R₂ is a hydrogen; R₃ is, a halol; and R₆ is a substituted or unsubstituted phenyl, and the substituted phenyl group is substituted with up to three substituents that is a hydrogen, a methyl, or a halogen.

As used herein, the term ‘substituent’ refers to atom or atomic group that replaces the hydrogen atoms of the molecule. As used herein, ‘optionally substituted’ substituent refers to substituents that each of the replicable hydrogen atoms on the substituents may be substituted by other atom or atomic group.

As used herein, the term ‘hydrocarbon group’ refers to alkyl group (saturated aliphatic group), alkenyl group (having at least one carbon-carbon double bond), alkynyl group (having at least one carbon-carbon triple bond); the ‘hydrocarbon group’ may be linear, branched or cyclic; the ‘hydrocarbon group’ may be aliphatic or aromatic.

As used herein, the term ‘cyclic hydrocarbon group’ refers to cycloalkyl group or cycloalkenyl group (having at least one carbon-carbon double bond), aromatic group; ‘cyclic hydrocarbon group’ may be monocyclic, bicyclic or multi-cyclic group; ‘cyclic hydrocarbon group’ may be spiral or fused ring.

As used herein, the term ‘hetero cyclic hydrocarbon group’ refers to cycloalkyl group or cycloalkenyl group (having at least one carbon-carbon double bond), aromatic group with one or more ring atoms are hetero atoms such as N, O, S, or combination thereof; ‘hetero cyclic hydrocarbon group’ may be monocyclic, bicyclic or multi-cyclic group; ‘hetero cyclic hydrocarbon group’ may be spiral or fused ring.

As used herein, the term ‘substituent’ include but not limited to: halogen (F, Cl, Br, I), —OR₂₆, —OC(═O) R₂₆, —OC(═O)N R₂₆R₂₇, ═O, —SR₂₆, —SOR₂₆, —SO₂R₂₆, —SO₂N R₂₆R₂₇, —C(═O)R₂₆, —C(═O)OR₂₆, —C(═O)N R₂₆R₂₇, —R₂₆CN, —NR₂₆R₂₇, —NHC(═O)R₂₆, —NHC(═O)N R₂₆R₂₇, —NHC(═S)N R₂₆R₂₇, halogenated (F, Cl, Br, I) hydrocarbon; and each of R₂₆ and R₂₇ is independently selected from H or optionally substituted C₁-C₈ hydrocarbon group.

The compounds described in the present invention that are acidic in nature can form pharmaceutically acceptable salts by reacting with physiologically compatible organic or inorganic bases, such as readily soluble alkali and alkaline earth salts, and salts formed from reacting with ammonia, N-methyl-glucamine, dimethyl-glucamine, ethyl-glucamine, lysine, ethanolamine, glucosamine, sarcosine, serine, tris(hydroxymethyl)aminomethane, 1-amino-2,3,4-butanetriol.

The compounds described in the present invention that are basic in nature can form pharmaceutically acceptable salts by reacting with physiologically compatible organic or inorganic acids, such as the salts formed by reacting with hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, toluene-sulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, oxalic acid, malonic acid, salicylic acid, malic acid, fumaric acid, maleic acid, acetic acid, ascorbic acid.

The compounds in the present invention may be pure chiral compounds, racemic mixtures, optically active compounds, pure diastereomers, or mixed diastereomers.

The present invention provides PIM kinase inhibitors which include the following compounds:

6-(2,6-difluorophenyl)-5-fluoro-N-(4-(piperidin-4-ylmethoxy)pyrimidin-5-yl)picolinamide, N-(4-(azetidin-3-ylmethoxy)pyrimidin-5-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide, 6-(2,6-difluorophenyl)-5-fluoro-N-(4-(piperidin-4-yloxy)pyrimidin-5-yl)picolinamide, 6-(2,6-difluorophenyl)-5-fluoro-N-(4-(pyrrolidin-3-yloxy)pyrimidin-5-yl)picolinamide, 6-(2,6-difluorophenyl)-5-fluoro-N-(4-(piperidin-3-yloxy)pyrimidin-5-yl)picolinamide, N-(4-(azocan-4-yloxy)pyrimidin-5-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide, 6-(2,6-difluorophenyl)-5-fluoro-N-(4-(piperidin-3-ylmethoxy)pyrimidin-5-yl)picolinamide, 6-(2,6-difluorophenyl)-5-fluoro-N-(4-(pyrrolidin-3-ylmethoxy)pyrimidin-5-yl)picolinamide, N-(4-(azetidin-3-yloxy)pyrimidin-5-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide, N-(4-(((1r,4r)-4-aminocyclohexyl)oxy)pyrimidin-5-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide, N-(4-((3-aminocyclohexyl)oxy)pyrimidin-5-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide, N-(4-(3-aminopropoxyl)pyrimidin-5-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide, 6-(2,6-difluorophenyl)-5-fluoro-N-(4-(3-(methylamino)propoxy)pyrimidin-5-yl)picolinamide, 6-(2,6-difluorophenyl)-N-(4-(3-(dimethylamino)propoxy)pyrimidin-5-yl)-5-fluoropicolinamide, N-(4-(4-aminobutoxyl)pyrimidin-5-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide, 6-(2,6-difluorophenyl)-5-fluoro-N-(4-(4-(methylamino)butoxy)pyrimidin-5-yl)picolinamide, 6-(2,6-difluorophenyl)-5-fluoro-N-(4-(3-hydroxypropoxyl)pyrimidin-5-yl)picolinamide, 6-(2,6-difluorophenyl)-5-fluoro-N-(4-(3-hydroxybutoxyl)pyrimidin-5-yl)picolinamide, 6-(2,6-difluorophenyl)-5-fluoro-N-(4-(4-hydroxybutoxyl)pyrimidin-5-yl)picolinamide, 6-(2,6-difluorophenyl)-5-fluoro-N-(4-((4-hydroxy-4-methylpentyl)oxy) pyrimidin-5-yl)picolinamide, 6-(2,6-difluorophenyl)-N-(4-(3,4-dihydroxybutoxyl)pyrimidin-5-yl)-5-fluoropicolinamide, N-(4-(3-amino-4-hydroxybutoxy)pyrimidin-5-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide, 6-(2,6-difluorophenyl)-5-fluoro-N-(4-((tetrahydro-2H-pyran-4-yl)methoxy)pyrimidin-5-yl)picolinamide, 3-amino-6-(2,6-difluorophenyl)-5-fluoro-N-(4-(piperidin-4-ylmethoxy)pyrimidin-5-yl)picolinamide, 3-amino-6-(2,6-difluorophenyl)-5-fluoro-N-(4-(pyrrolidin-3-yloxy)pyrimidin-5-yl)picolinamide, 3-amino-6-(2,6-difluorophenyl)-5-fluoro-N-(4-(piperidin-4-yloxy)pyrimidin-5-yl)picolinamide, 3-amino-N-(4-(azepan-4-yloxy)pyrimidin-5-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide, 3-amino-N-(4-(((1r,4r)-4-aminocyclohexyl)oxy)pyrimidin-5-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide, 3-amino-6-(2,6-difluorophenyl)-5-fluoro-N-(4-(pyrrolidin-3-ylmethoxy)pyrimidin-5-yl)picolinamideyl)picolinamide, N-(4-((1-amino-3-chloropropan-2-yl)oxy)pyrimidin-5-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide, N-(4-(3-amino-2-(chloromethyl)propoxy)pyrimidin-5-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide.

The present invention also provides the methods of synthesis of the above PIM kinase inhibitors. The compounds in the present invention are made from commercially available starting materials and reagents. The present invention is illustrated in the following reaction scheme:

(1) The general procedure for the synthesis of compounds of Formula II:

Alcohol B (1.1 eq.), protected or unprotected, reacts with a base, for example, NaH (1.1 eq.), in a solvent, for example, THF, at room temperature (25° C.) for 1 hour, then reacts with 5-amino-4-chloropyrimidine A (1 eq.) at heated conditions, for example, 100° C. for 1-10 hours to form aminopyrimidine ether C. Protected or unprotected aromatic carboxylic acid D (1 eq.), in the presence of a coupling reagent, for example, HATU (1-1.5 eq.), a base, for example, DIEA (3 eq.), in a solvent, for example DMF, at heated conditions, for example 40° C., reacts with amine C (1 eq.) for 0.5-8 hours to form ether E. If there is no protecting group in E, then E is final ether product of Formula I or II. If E is protected by protecting group, for example, BOC or trimethylsilyl group, it's deprotected by treating with trifluoroacetic acid (10-100 eq.) with equal volume of dichloromethane at room temperature (25° C.) for 1-16 hours. The final ether product F of Formula I or II is obtained after removing the solvent in vacuo at room temperature (25° C.).

The present invention also provides the pharmaceutical application of the above PIM kinase inhibitors.

The PIM kinase assays show that all compounds in all the examples can significantly inhibit the PIM-1, PIM-2 and PIM-3 activity. The IC₅₀ of these compounds range from 0.1 nM to 50 nM. Therefore, the PIM kinase inhibitors in the present invention may be used for pharmaceuticals.

The present invention provides the use of the above PIM kinase inhibitors as drugs to treat or prevent hematological cancers such as human chronic lymphocytic leukemia, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic myelogenous leukemia (CML), Non-Hodgkin's Lymphoma (NHL) and Multiple Myeloma (MM) and solid tumors such as pancreatic cancers, prostate cancers, liver cancers, gastric cancer and bladder cancer, and the PIM kinase inhibitors of the present invention further may be used to treat or prevent multi drug resistance, and T cell-mediated diseases such Inflammatory Bowel Disease (IBD). The present invention further provides the use of the PIM kinase inhibitors of the present invention as drugs to treat or prevent autoimmune diseases.

The drugs in present invention use PIM kinase inhibitors as active ingredients along with pharmaceutical carriers and adjuvants. The present invention provides the new application of PIM kinase inhibitors and has significant clinical value.

EXAMPLES

The following examples are set forth for illustration only to help understand the invention described herein and not to be construed as limiting the present invention in any manner.

Example 1 Synthesis of 6-(2,6-difluorophenyl)-5-fluoro-N-(4-(piperidin-4-ylmethoxy)pyrimidin-5-yl)picolinamide (1)

(1) tert-butyl 4-(((5-aminopyrimidin-4-yl)oxy)methyl)piperidine-1-carboxylate (C1)

At room temperature, NaH (67 mg, 2.79 mmol) was added to a solution of tert-butyl 4-(hydroxymethyl)piperidine-1-carboxylate (B1) (500 mg, 2.32 mmol) in THF (tetrahydrofuran) (10 mL) and stirred for 1 hour. 4-chloropyrimidin-5-amine (A) (346 mg, 2.67 mmol) was then added. The reaction mixture was then heated to 100° C. under nitrogen and stirred for 4 hours, cooled to room temperature (20-30° C.) and concentrated in vacuo. The residue was purified with flash column (eluent: 10-30% ethyl acetate/petroleum ether) to obtain the product C1 (370 mg, 1.2 mmol).

(2) Synthesis of tert-butyl 4-4(5-(6-(2,6-difluorophenyl)-5-fluoropicolinamido)pyrimidin-4-yl)oxy)methyl)piperidine-1-carboxylate (E1)

Compound (C1) (49 mg, 0.16 mmol), 6-(2,6-difluorophenyl)-5-fluoropicolinic acid (D1) (40 mg, 0.16 mmol, HATU (72 mg, 0.19 mmol) and DIEA (88 μL, 0.507 mmol) are mixed in DMF (5 mL) and stirred at 50° C. for 1 hour. The reaction mixture was cooled to room temperature and diluted with ethyl acetate (50 mL), washed with brine, dried over Na₂SO₄, and concentrated in vacuo. The residue was purified with flash column (eluent: 10-30% ethyl acetate/petroleum ether) to obtain the product E1 (30 mg, 0.055 mmol).

(3) Synthesis of 6-(2,6-difluorophenyl)-5-fluoro-N-(4-(piperidin-4-ylmethoxy)pyrimidin-5-yl)picolinamide (1)

At room temperature, TFA (trifluoroacetic acid) (0.5 mL) was added to a solution of Compound E1 (20 mg, 0.037 mmol) in CH₂Cl₂ (1 mL) and stirred for 10 min. The mixture was the concentrated in vacuo. The residue was dissolved in CH₂Cl₂ (10 mL) and washed with NaOH (5 mL) and brine (5 mL), dried over Na₂SO₄, and concentrated in vacuo to obtain the title compound 1 (12 mg, 0.025 mmol).

Example 2 Synthesis of N-(4-(azetidin-3-ylmethoxy)pyrimidin-5-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (2)

Following the procedure described in Example 1, and substituting compound B1 in Step (1) with tert-butyl 3-(hydroxymethyl)azetidine-1-carboxylate (B2), the title compound 2 was obtained.

Example 3 Synthesis of 6-(2,6-difluorophenyl)-5-fluoro-N-(4-(piperidin-4-yloxy)pyrimidin-5-yl)picolinamide (3)

Following the procedure described in Example 1, and substituting compound B1 in Step (1) with tert-butyl 4-hydroxypiperidine-1-carboxylate (B3), the title compound 3 was obtained.

Example 4 Synthesis of 6-(2,6-difluorophenyl)-5-fluoro-N-(4-(pyrrolidin-3-yloxy)pyrimidin-5-yl)picolinamide (4)

Following the procedure described in Example 1, and substituting Compound B1 in Step (1) with tert-butyl 3-hydroxypyrrolidine-1-carboxylate (B4), the title compound 4 was obtained.

Example 5 Synthesis of 6-(2,6-difluorophenyl)-5-fluoro-N-(4-(piperidin-3-yloxy)pyrimidin-5-yl)picolinamide (5)

Following the procedure described in Example 1, and substituting Compound B1 in Step (1) with tert-butyl 3-hydroxypiperidine-1-carboxylate (B5), the title compound 5 was obtained.

Example 6 Synthesis of N-(4-(azepan-4-yloxy)pyrimidin-5-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (6)

Following the procedure described in Example 1, and substituting Compound B1 in Step (1) with tert-butyl 4-hydroxyazepane-1-carboxylate (B6), the title compound 6 was obtained.

Example 7 Synthesis of 6-(2,6-difluorophenyl)-5-fluoro-N-(4-(piperidin-3-ylmethoxy)pyrimidin-5-yl)picolinamide (7)

Following the procedure described in Example 1, and substituting Compound B1 in Step (1) with tert-butyl 3-(hydroxymethyl)piperidine-1-carboxylate (B7), the title compound 7 was obtained.

Example 8 Synthesis of 6-(2,6-difluorophenyl)-5-fluoro-N-(4-(pyrrolidin-3-ylmethoxy)pyrimidin-5-yl)picolinamide (8)

Following the procedure described in Example 1, and substituting Compound B1 in Step (1) with tert-butyl 3-(hydroxymethyl)pyrrolidine-1-carboxylate (B8), the title compound 8 was obtained.

Example 9 Synthesis of N-(4-(azetidin-3-yloxy)pyrimidin-5-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (9)

Following the procedure described in Example 1, and substituting Compound B1 in Step (1) with tert-butyl 3-(hydroxymethyl)azetidine-1-carboxylate (B9), the title compound 9 was obtained.

Example 10 Synthesis of N-(4-(((1r,4r)-4-aminocyclohexyl)oxy)pyrimidin-5-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (10)

Following the procedure described in Example 1, and substituting Compound B1 in Step (1) with tert-butyl ((1r,4r)-4-hydroxycyclohexyl)carbamate (B10), the title compound 10 was obtained.

Example 11 Synthesis of N-(4-((3-aminocyclohexyl)oxy)pyrimidin-5-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (11)

Following the procedure described in Example 1, and substituting Compound 1E in Step (1) with tert-butyl(3-hydroxycyclohexyl)carbamate (B11), the title compound 11 was obtained.

Example 12 Synthesis of N-(4-(3-aminopropoxyl)pyrimidin-5-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (12)

Following the procedure described in Example 1, and substituting Compound B1 in Step (1) with tert-butyl(3-hydroxypropyl)carbamate (B12), the title compound 12 was obtained.

Example 13 Synthesis of 6-(2,6-difluorophenyl)-5-fluoro-N-(4-(3-(methylamino)propoxy)pyrimidin-5-yl)picolinamide (13)

Following the procedure described in Example 1, and substituting Compound B1 in Step (1) with 3-(methylamino)propan-1-ol (B13), the title compound 13 was obtained.

Example 14 Synthesis of 6-(2,6-difluorophenyl)-N-(4-(3-(dimethylamino)propoxy)pyrimidin-5-yl)-5-fluoropicolinamide (14)

Following the procedure described in Example 1, and substituting Compound B1 in Step (1) with 3-(dimethylamino)propan-1-ol (B14), the title compound 14 was obtained.

Example 15 Synthesis of N-(4-(4-aminobutoxyl)pyrimidin-5-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (15)

Following the procedure described in Example 1, and substituting Compound B1 in Step (1) with tert-butyl(4-hydroxybutyl)carbamate (B15), the title compound 15 was obtained.

Example 16 Synthesis of 6-(2,6-difluorophenyl)-5-fluoro-N-(4-(4-(methylamino)butoxy)pyrimidin-5-yl)picolinamide (16)

Following the procedure described in Example 1, and substituting Compound B1 in Step (1) with tert-butyl(4-hydroxybutyl)(methyl)carbamate (B16), the title compound 16 was obtained.

Example 17 Synthesis of 6-(2,6-difluorophenyl)-5-fluoro-N-(4-(3-hydroxypropoxyl)pyrimidin-5-yl)picolinamide (17)

Following the procedure described in Example 1, and substituting Compound B1 in Step (1) with propane-1,3-diol (B17), the title compound 17 was obtained.

Example 18 Synthesis of 6-(2,6-difluorophenyl)-5-fluoro-N-(4-(3-hydroxybutoxyl)pyrimidin-5-yl)picolinamide (18)

Following the procedure described in Example 1, and substituting Compound B1 in Step (1) with butane-1,3-diol (B18), the title compound 18 was obtained.

Example 19 Synthesis of 6-(2,6-difluorophenyl)-5-fluoro-N-(4-(4-hydroxybutoxyl)pyrimidin-5-yl)picolinamide (19)

Following the procedure described in Example 1, and substituting Compound B1 in Step (1) with butane-1,4-diol (B4), the title compound 19 was obtained.

Example 20 Synthesis of 6-(2,6-difluorophenyl)-5-fluoro-N-(4-((4-hydroxy-4-methylpentyl)oxy)pyrimidin-5-yl)picolinamide (20)

Following the procedure described in Example 1, and substituting Compound B1 in Step (1) with 4-methylpentane-1,4-diol (20), the title compound 20 was obtained.

Example 21 Synthesis of 6-(2,6-difluorophenyl)-N-(4-(3,4-dihydroxybutoxyl)pyrimidin-5-yl)-5-fluoropicolinamide (21)

(1) The synthesis of 6-(2,6-difluorophenyl)-N-(4-(2-(2,2-dimethyl-1,3-dioxolan-4-yl)ethoxy)pyrimidin-5-yl)-5-fluoropicolinamide (E21)

Following the procedure described in Example 1, Step (1) and (2), and substituting Compound B1 in Step (1) with 2-(2,2-dimethyl-1,3-dioxolan-4-yl)ethanol (B21), compound E21 was obtained.

(2) 6-(2,6-difluorophenyl)-N-(4-(3,4-dihydroxybutoxyl)pyrimidin-5-yl)-5-fluoropicolinamide (21)

At room temperature (25° C.), to a solution of 6-(2,6-difluorophenyl)-N-(4-(2-(2,2-dimethyl-1,3-dioxolan-4-yl)ethoxy)pyrimidin-5-yl)-5-fluoropicolinamide (E21) (20 mg, 0.042 mmol) in methanol (2 mL) was added concentrated HCl (0.5 mL) and the solution was stirred for 4 hours. 10% Na₂CO₃ solution was added to neutralize the solution to pH=7, the water (20 mL) was added and a precipitate was formed. An off white solid product title compound 21 (11 mg, 0.0252 mmol) was obtained after filtration and air drying at 25° C.

Example 22 Synthesis of 6-(2,6-difluorophenyl)-5-fluoro-N-(4-((tetrahydro-2H-pyran-4-yl)methoxy)pyrimidin-5-yl)picolinamide (22)

Following the procedure described in Example 1, and substituting Compound B1 in Step (1) with (tetrahydro-2H-pyran-4-yl)methanol (B22), the title compound 22 was obtained.

Example 23 Synthesis of 3-amino-6-(2,6-difluorophenyl)-5-fluoro-N-(4-(piperidin-4-ylmethoxy)pyrimidin-5-yl)picolinamide (23)

Following the procedure described in Example 1, and substituting Compound D1 in Step (2) with 3-amino-6-(2,6-difluorophenyl)-5-fluoropicolinic acid (D2), the title compound 23 was obtained.

Example 24 Synthesis of 3-amino-6-(2,6-difluorophenyl)-5-fluoro-N-(4-(pyrrolidin-3-yloxy)pyrimidin-5-yl)picolinamide (24)

Following the procedure described in Example 23, and substituting Compound B1 in Step (1) with B4, the title compound 24 was obtained.

Example 25 Synthesis of 3-amino-6-(2,6-difluorophenyl)-5-fluoro-N-(4-(piperidin-4-yloxy)pyrimidin-5-yl)picolinamide (25)

Following the procedure described in Example 23, and substituting Compound B1 in Step (1) with B3, the title compound 25 was obtained.

Example 26 Synthesis of 3-amino-N-(4-(azepan-4-yloxy)pyrimidin-5-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (26)

Following the procedure described in Example 23, and substituting Compound B1 in Step (1) with B6, the title compound 26 was obtained.

Example 27 Synthesis of 3-amino-N-(4-(((1r,4r)-4-aminocyclohexyl)oxy)pyrimidin-5-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (27)

Following the procedure described in Example 23, and substituting Compound B1 in Step (1) with B10, the title compound 27 was obtained.

Example 28 Synthesis of 3-amino-6-(2,6-difluorophenyl)-5-fluoro-N-(4-(pyrrolidin-3-ylmethoxy)pyrimidin-5-yl)picolinamideyl)picolinamide (28)

Following the procedure described in Example 23, and substituting Compound B1 in Step (1) with B8, the title compound 28 was obtained.

Example 29 Synthesis of N-(4-((1-amino-3-chloropropan-2-yl)oxy)pyrimidin-5-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (29)

To a solution of 4M HCl in methanol (1 mL) at room temperature was added compound 9 (20 mg, 0.050 mmol). The solution was stirred for 4 hours. The solvent was then removed and the residue was washed with ether and then dried under vacuo to get an off white solid product 29 (21 mg, 0.044 mmol)

Example 30 Synthesis of N-(4-(3-amino-2-(chloromethyl)propoxy)pyrimidin-5-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (30)

Following the procedure described in Example 29, and substituting Compound 9 with 2, the title compound 30 was obtained.

TABLE I Analytical data of the compounds described in the examples of the present invention Name NMR MS 6-(2,6-difluorophenyl)-5-fluoro-N- 1H NMR (400 MHz, DMSO-d6) δ: 1.98 (bs, 2H), 444 (M + 1) (4-(piperidin-4- 1.20-2.10 (m, 2H), 2.70-2.90 (m, 2H), 2.90-3.70 (m, ylmethoxy)pyrimidin-5- 5H), 4.32 (bs, 2H), 7.43 (t, 8, 2H), 7.69-7.77 (m, 1H), yl)picolinamide 8.25 (t, J = 10, 1H), 8.39 (dd, J = 8, 4, 1H), 8.62 (s, 1H), 9.05 (bs, 2H), 9.25 (s, 1H), 10.20 (s, 1H) N-(4-(azetidin-3- 1H NMR (400 MHz, DMSO-d6) δ: 1.99 (bs, 1H), 416 (M + 1) ylmethoxy)pyrimidin-5-yl)-6-(2,6- 3.60-4.40 (m, 4H), 4.63 (d, J = 6, 2H), 7.41 (t, 8, 2H), difluorophenyl)-5- 7.46-7.76 (m, 1H), 8.25 (t, J = 10, 1H), 8.39 (dd, J = 8, fluoropicolinamide 4, 1H), 8.63 (s, 1H), 9.05 (bs, 2H), 9.25 (s, 1H), 10.12 (s, 1H) 6-(2,6-difluorophenyl)-5-fluoro-N- 1H NMR (400 MHz, DMSO-d6) δ: 1.80-2.00 (m, 430 (M + 1) (4-(piperidin-4-yloxy)pyrimidin-5- 2H), 2.20 (bs, 2H), 3.04 (bs, 2H), 3.21 (bs, 2H), yl)picolinamide 5.12 (bs, 1H), 7.43 (t, 8, 2H), 7.69-7.77 (m, 1H), 8.26 (t, J = 8, 1H), 8.40 (dd, J = 8, 4, 1H), 8.62 (s, 1H), 8.88 (bs, 1H), 9.17 (bs, 1H), 9.35 (s, 1H), 10.21 (s, 1H) 6-(2,6-difluorophenyl)-5-fluoro-N- 1H NMR (400 MHz, DMSO-d6) δ: 2.10-2.22 (m, 416 (M + 1) (4-(pyrrolidin-3-yloxy)pyrimidin-5- 1H), 2.28-2.31 (m, 1H), 3.00-3.02 (m, 1H), yl)picolinamide 3.28-3.31 (m, 1H), 3.30-3.34 (m, 2H), 5.71 (bs, 1H), 7.42 (t, J = 8, 2H), 7.69-7.77 (m, 1H), 8.26 (t, J = 8, 1H), 8.38 (dd, J = 10, 4, 1H), 8.64 (s, 1H), 9.11 (bs, 1H), 9.29 (s, 1H), 9.30 (bs, 1H), 10.17 (s, 1H) 6-(2,6-difluorophenyl)-5-fluoro-N- 1H NMR (400 MHz, DMSO-d6) δ: 1.39-1.50 (m, 430 (M + 1) (4-(piperidin-3-yloxy)pyrimidin-5- 1H), 1.66-1.81 (m, 2H), 2.03-2.08 (m, 1H), yl)picolinamide 2.21-2.28 (m, 1H), 2.54-2.60 (m, 1H), 2.70-2.76 (m, 2H), 3.06-3.10 (m, 1H), 5.45 (bs, 1H), 7.43 (t, 8, 2H), 7.69-7.77 (m, 1H), 8.26 (t, J = 8, 1H), 8.41 (dd, J = 8, 4, 1H), 8.61 (s, 1H), 8.68 (bs, 1H), 9.17 (bs, 1H), 9.35 (s, 1H), 10.20 (s, 1H) N-(4-(azepan-4-yloxy)pyrimidin-5- 1H NMR (400 MHz, DMSO-d6) δ: 1.68 (m, 1H), 444 (M + 1) yl)-6-(2,6-difluorophenyl)-5- 2.06-2.08 (m, 2H), 2.07-2.15 (m, 3H), 2.90-3.00 (m, fluoropicolinamide 4H), 5.41-5.44 (m, 1H), 7.43 (t, 8, 2H), 7.69-7.77 (m, 1H), 8.26 (t, J = 8, 1H), 8.41 (dd, J = 8, 4, 1H), 8.61 (s, 1H), 8.68 (bs, 1H), 9.17 (bs, 1H), 9.35 (s, 1H), 10.20 (s, 1H) 6-(2,6-difluorophenyl)-5-fluoro-N- 1H NMR (400 MHz, DMSO-d6) δ: 1.39-1.50 (m, 444 (M + 1) (4-(piperidin-3- 1H), 1.66-1.81 (m, 2H), 2.03-2.08 (m, 1H), ylmethoxy)pyrimidin-5- 2.21-2.28 (m, 1H), 2.54-2.60 (m, 1H), 2.70-2.76 (m, 2H), yl)picolinamide 3.06-3.10 (m, 1H), 4.37 (bs, 2H), 7.42 (t, 8, 2H), 7.45-7.77 (m, 1H), 8.25 (t, J = 8, 1H), 8.40 (dd, J = 8, 4, 1H), 8.63-8.64 (m, 1H), 9.17 (bs, 2H), 9.25 (s, 1H), 10.15 (s, 1H) 6-(2,6-difluorophenyl)-5-fluoro-N- 1H NMR (400 MHz, DMSO-d6) δ: 1.67-1.74 (m, 430 (M + 1) (4-(pyrrolidin-3- 1H), 2.08-2.17 (m, 1H), 2.71-2.78 (m, 1H), ylmethoxy)pyrimidin-5- 2.83-2.97 (m, 2H), 3.02-3.08 (m, 1H), 3.16-3.21 (m, 1H), yl)picolinamide 4.42-4.45 (m, 2H), 7.44 (t, 8, 2H), 7.71-7.77 (m, 1H), 8.26 (t, J = 8, 1H), 8.39 (dd, J = 8, 4, 1H), 8.62 (s, 1H), 9.07 (bs, 1H), 9.15 (bs, 1H), 9.28 (s, 1H), 10.12 (s, 1H) N-(4-(azetidin-3-yloxy)pyrimidin-5- 1H NMR (400 MHz, DMSO-d6) δ: 4.00-4.10 (m, 402 (M + 1) yl)-6-(2,6-difluorophenyl)-5- 2H), 4.43-4.51 (m, 2H), 5.40-5.50 (m, 1H), 7.40 (t, 8, fluoropicolinamide 2H), 7.70-7.77 (m, 1H), 8.26 (t, J = 8, 1H), 8.40 (dd, J = 8, 4, 1H), 8.61 (s, 1H), 9.07 (bs, 1H), 9.25 (bs, 1H), 9.27 (s, 1H), 10.17 (s, 1H) N-(4-(((1r,4r)-4- 1H NMR (400 MHz, DMSO) δ: 1.09-1.51 (m, 2H), 444 (M + 1) aminocyclohexyl)oxy)pyrimidin-5- 1.65-1.69 (m, 2H), 1.98-2.02 (m, 2H), 2.20-2.23 (m, yl)-6-(2,6-difluorophenyl)-5- 2H), 2.85-2.90 (m, 1H), 5.35-5.41 (m, 1H), 7.22 (bs, fluoropicolinamide 3H), 7.40 (t, 8, 2H), 7.70-7.77 (m, 1H), 8.26 (t, J = 8, 1H), 8.40 (dd, J = 8, 4, 1H), 8.61 (s, 1H), 9.26 (s, 1H), 10.18 (s, 1H) N-(4-((3- 1H NMR (400 MHz, DMSO) δ: 1.10-1.50 (m, 5H), 444 (M + 1) aminocyclohexyl)oxy)pyrimidin-5- 2.60-2.80 (m, 3H), 3.0-3.50 (m, 1H), 3.95-4.05 (m, yl)-6-(2,6-difluorophenyl)-5- 0.7H), 4.4 (bs, 0.3H), 7.22 (bs, 3H), 7.39 (t, 8, 2H), fluoropicolinamide 7.70-7.77 (m, 1H), 8.26 (t, J = 8, 1H), 8.40 (dd, J = 8, 4, 1H), 8.61 (s, 1H), 9.26 (s, 1H), 10. 25 (s, 1H) N-(4-(3-aminopropoxy)pyrimidin-5- 1H NMR (400 MHz, DMSO-d6) δ: 1.84 (bs, 2H), 444 (M + 1) yl)-6-(2,6-difluorophenyl)-5- 2.80 (bs, 2H), 4.21 (bs, 2H), 7.22 (bs, 3H), 7.43 (t, fluoropicolinamide J = 8, 2H), 7.65 (d, J = 6, 1H), 7.40 (t, 8, 2H), 7.70-7.77 (m, 1H), 8.26 (t, J = 8, 1H), 8.40 (dd, J = 8, 4, 1H), 8.61 (s, 1H), 9.26 (s, 1H), 10.20 (s, 1H) 6-(2,6-difluorophenyl)-5-fluoro-N- 1H NMR (400 MHz, DMSO-d6) δ: 1.85 (bs, 2H), 418 (M + 1) (4-(3- 2.80 (bs, 2H), 2.90 (s, 3H), 4.22 (bs, 2H), 7.42 (t, 8, (methylamino)propoxy)pyrimidin- 2H), 7.45-7.77 (m, 1H), 8.25 (t, J = 8, 1H), 8.40 (dd, 5-yl)picolinamide J = 8, 4, 1H), 8.63 (s, 1H), 9.17 (bs, 2H), 9.25 (s, 1H), 10.16 (s, 1H) 6-(2,6-difluorophenyl)-N-(4-(3- 1H NMR (400 MHz, DMSO-d6) δ: 1.85 (bs, 2H), 432 (M + 1) (dimethylamino)propoxy)pyrimidin- 2.79 (bs, 2H), 2.92 (s, 6H), 4.21 (bs, 2H), 7.42 (t, 8, 5-yl)-5-fluoropicolinamide 2H), 7.45-7.77 (m, 1H), 8.25 (t, J = 8, 1H), 8.40 (dd, J = 8, 4, 1H), 8.63 (s, 1H), 9.17 (bs, 1H), 9.26 (s, 1H), 10.20 (s, 1H) N-(4-(4-aminobutoxy)pyrimidin-5- 1H NMR (400 MHz, DMSO-d6) δ: 1.50-1.57 (m, 418 (M + 1) yl)-6-(2,6-difluorophenyl)-5- 2H), 1.75-1.78 (m, 2H), 2.81-2.84 (m, 2H), 4.21 (t, fluoropicolinamide J = 6, 2H), 7.22 (bs, 3H), 7.43 (t, J = 8, 2H), 7.65 (d, J = 6, 1H), 7.40 (t, 8, 2H), 7.70-7.77 (m, 1H), 8.26 (t, J = 8, 1H), 8.40 (dd, J = 8, 4, 1H), 8.61 (s, 1H), 9.26 (s, 1H), 10.20 (s, 1H) 6-(2,6-difluorophenyl)-5-fluoro-N- 1H NMR (400 MHz, DMSO-d6) δ: 1.49-1.60 (m, 432 (M + 1) (4-(4- 2H), 1.79-1.84 (m, 2H), 2.81-2.82 (m, 2H), 2.92 (s, (methylamino)butoxy)pyrimidin-5- 3H), 4.30 (t, J = 6, 2H), 7.42 (t, 8, 2H), 7.45-7.77 (m, yl)picolinamide 1H), 8.25 (t, J = 8, 1H), 8.40 (dd, J = 8, 4, 1H), 8.63 (s, 1H), 9.10 (bs, 2H), 9.26 (s, 1H), 10.13 (s, 1H) 6-(2,6-difluorophenyl)-5-fluoro-N- 1H NMR (400 MHz, DMSO-d6) δ: 1.96-1.98 (m, 405 (M + 1) (4-(3-hydroxypropoxy)pyrimidin-5- 2H), 3.60-3.63 (m, 2H), 4.26 (t, J = 6, 2H), 4.56 (bs, yl)picolinamide 1H), 7.42 (t, 8, 2H), 7.45-7.77 (m, 1H), 8.26 (t, J = 8, 1H), 8.41 (dd, J = 8, 4, 1H), 8.62 (s, 1H), 9.25 (s, 1H), 10.25 (s, 1H) 6-(2,6-difluorophenyl)-5-fluoro-N- 1H NMR (400 MHz, DMSO-d6) δ: 1.07 (s, 3H), 419 (M + 1) (4-(3-hydroxybutoxy)pyrimidin-5- 1.69-1.85 (m, 2H), 3.45-3.55 (m, 1H), 4.15-4.25 (m, yl)picolinamide 2H), 4.58 (s, 1H), 7.42 (t, 8, 2H), 7.45-7.77 (m, 1H), 8.26 (t, J = 8, 1H), 8.42 (dd, J = 8, 4, 1H), 8.62 (s, 1H), 9.25 (s, 1H), 10.21 (s, 1H) 6-(2,6-difluorophenyl)-5-fluoro-N- 1H NMR (400 MHz, DMSO-d6) δ: 1.45-1.52 (m, 419 (M + 1) (4-(4-hydroxybutoxy)pyrimidin-5- 2H), 1.74-1.78 (m, 2H), 3.35-3.45 (m, 2H), 4.22 (t, yl)picolinamide J = 6, 2H), 4.43 (bs, 1H), 7.42 (t, 8, 2H), 7.45-7.77 (m, 1H), 8.26 (t, J = 8, 1H), 8.41 (dd, J = 8, 4, 1H), 8.62 (s, 1H), 9.25 (s, 1H), 10.25 (s, 1H) 6-(2,6-difluorophenyl)-5-fluoro-N- 1H NMR (400 MHz, DMSO-d6) δ: 1.11 (s, 6H), 447 (M + 1) (4-((4-hydroxy-4- 1.40-1.47 (m, 2H), 1.69-1.80 (m, 2H), 4.21 (t, J = 7, methylpentyl)oxy)pyrimidin-5- 2H), 7.42 (t, 8, 2H), 7.45-7.75 (m, 1H), 8.26 (t, J = 8, yl)picolinamide 1H), 8.43 (dd, J = 8, 4, 1H), 8.62 (s, 1H), 9.25 (s, 1H), 10.20 (s, 1H) 6-(2,6-difluorophenyl)-N-(4-(3,4- 1H NMR (400 MHz, DMSO-d6) δ: 1.92-2.10 (m, 435 (M + 1) dihydroxybutoxy)pyrimidin-5-yl)-5- 2H), 3.29 (s, 1H), 3.70 (s, 2H), 4.15-4.35 (m, 2H), fluoropicolinamide 4.50 (s, 1H), 4.65 (d, J = 5.04, 1H), 7.42 (t, 8, 2H), 7.45-7.77 (m, 1H), 8.26 (t, J = 8, 1H), 8.42 (dd, J = 8, 4, 1H), 8.62 (s, 1H), 9.25 (s, 1H), 10.13 (s, 1H) 6-(2,6-difluorophenyl)-5-fluoro-N- 1H NMR (400 MHz, DMSO-d6) δ: 1.70-1.85 (m, 445 (M + 1) (4-((tetrahydro-2H-pyran-4- 1H), 2.20-2.38 (m, 2H), 2.59-2.69 (m, 2H), yl)methoxy)pyrimidin-5- 3.74-3.85 (m, 2H), 3.97-4.05 (m, 4H), 7.42 (t, 8, 2H), yl)picolinamide 7.45-7.75 (m, 1H), 8.26 (t, J = 8, 1H), 8.42 (dd, J = 8, 4, 1H), 8.62 (s, 1H), 9.25 (s, 1H), 10.19 (s, 1H) 3-amino-6-(2,6-difluorophenyl)-5- 1H NMR (400 MHz, DMSO-d6) δ 1.68-1.85 (m, 1H), 459 (M + 1) fluoro-N-(4-(piperidin-4- 2.23-2.38 (m, 2H), 2.59-2.69 (m, 2H), 3.74-3.85 (m, ylmethoxy)pyrimidin-5- 2H), 3.97-4.05 (m, 4H), 7.20-7.31 (m, 3H), 7.34 (d, yl)picolinamide 1H), 7.36 (bs, 2H), 7.50-7.60 (m, 1H), 8.43 (dd, J = 8, 4, 1H), 8.81 (s, 1H), 9.13 (bs, 2H), 10.24 (s, 1H) 3-amino-6-(2,6-difluorophenyl)-5- 1H NMR (400 MHz, DMSO-d6) δ: 2.05-2.20 (m, 431 (M + 1) fluoro-N-(4-(pyrrolidin-3- 1H), 2.28-2.31 (m, 1H), 3.00-3.02 (m, 1H), yloxy)pyrimidin-5-yl)picolinamide 3.28-3.31 (m, 1H), 3.30-3.34 (m, 2H), 5.68 (bs, 1H), 7.20-7.31 (m, 3H), 7.35 (d, 1H), 7.36 (bs, 2H), 7.52-7.62 (m, 1H), 8.44 (dd, J = 8, 4, 1H), 8.83 (s, 1H), 9.10 (bs, 2H), 10.14 (s, 1H) 3-amino-6-(2,6-difluorophenyl)-5- 1H NMR (400 MHz, DMSO-d6) δ: 1.75-1.95 (m, 445 (M + 1) fluoro-N-(4-(piperidin-4- 2H), 2.20 (bs, 2H), 3.04 (bs, 2H), 3.21 (bs, 2H), yloxy)pyrimidin-5-yl)picolinamide 5.12 (bs, 1H), 7.44 (t, 8, 2H), 7.71-7.77 (m, 1H), 8.26 (t, J = 8, 1H), 8.40 (dd, J = 8, 4, 1H), 8.62 (s, 1H), 8.88 (bs, 1H), 9.25 (bs, 1H), 9.37 (s, 1H), 10.23 (s, 1H) 3-amino-N-(4-(azepan-4- 1H NMR (400 MHz, DMSO-d6) δ: 1.68 (m, 1H), 459 (M + 1) yloxy)pyrimidin-5-yl)-6-(2,6- 2.06-2.08 (m, 2H), 2.05-2.15 (m, 3H), 2.90-3.00 (m, difluorophenyl)-5- 4H), 5.41-5.44 (m, 1H), 7.44 (t, 8, 2H), 7.71-7.77 (m, fluoropicolinamide 1H), 8.26 (t, J = 8, 1H), 8.40 (dd, J = 8, 4, 1H), 8.62 (s, 1H), 8.89 (bs, 1H), 9.18 (bs, 1H), 9.35 (s, 1H), 10.13 (s, 1H) 3-amino-N-(4-(((1r,4r)-4- 1H NMR (400 MHz, DMSO-d6) δ: 1.15-1.31 (m, 459 (M + 1) aminocyclohexyl)oxy)pyrimidin-5- 2H), 1.45-1.57 (m, 2H), 1.78-1.91 (m, 2H), yl)-6-(2,6-difluorophenyl)-5- 2.05-2.17 (m, 2H), 3.10 (bs, 1H), 4.90 (bs, 1H), 7.44 (t, 8, 2H), fluoropicolinamide 7.71-7.76 (m, 1H), 8.26 (t, J = 8, 1H), 8.41 (dd, J = 8, 4, 1H), 8.62 (s, 1H), 9.18 (bs, 2H), 9.35 (s, 1H), 10.19 (s, 1H) 3-amino-6-(2,6-difluorophenyl)-5- 1HNMR (400 MHz, DMSO-d6) δ: 2.02-2.18 (m, 1H), 445 (M + 1) fluoro-N-(4-(pyrrolidin-3- 2.28-2.30 (m, 1H), 3.00-3.02 (m, 1H), 3.28-3.31 (m, ylmethoxy)pyrimidin-5- 1H), 3.30-3.34 (m, 2H), 5.71 (bs, 1H), 7.22-7.30 (m, yl)picolinamideyl)picolinamide 3H), 7.34 (d, 1H), 7.36 (bs, 2H), 7.50-7.60 (m, 1H), 8.42 (dd, J = 8, 4, 1H), 8.82 (s, 1H), 9.17 (bs, 2H), 10.26 (s, 1H) N-(4-((1-amino-3-chloropropan-2- 1H NMR (400 MHz, CDCl3) δ: 3.14 (dd, J = 12, 8, 438 (M + 1) yl)oxy)pyrimidin-5-yl)-6-(2,6- 1H), 3.23 (dd, J = 10, 4, 1H), 3.78 (d, J = 8, 2H), difluorophenyl)-5- 4.15-4.31 (m, 1H), 7.40 (t, 8, 2H), 7.45-7.75 (m, 1H), fluoropicolinamide 8.27 (t, J = 8, 1H), 8.40 (dd, J = 8, 4, 1H), 8.60 (s, 1H), 9.20 (s, 1H), 10.05 (s, 1H) N-(4-(3-amino-2- 1H NMR (400 MHz, CDCl3) δ: 2.25-2.70 (m, 2H), 452 (M + 1) (chloromethyl)propoxy)pyrimidin- 2.90-3.05 (m, 1H), 3.65 (s, 1H), 3.79 (d, J = 8, 2H), 5-yl)-6-(2,6-difluorophenyl)-5- 4.20-4.40 (m, 2H), 7.42 (t, 8, 2H), 7.47-7.77 (m, 1H), fluoropicolinamide 8.26 (t, J = 8, 1H), 8.41 (dd, J = 8, 4, 1H), 8.62 (s, 1H), 9.19 (s, 1H), 10.00 (s, 1H)

Example 31

The biochemical assays used to test the activities of the compounds of the present invention and their results.

In the present invention, the PIM activities of the compounds were tested by BioDuro (Building E, No. 29 Life Science Park Road, Changing District, Beijing, 102206, P.R. China). The method used for testing is PIM Kinase Activity Assay-IMAP Fluorescence Polarization Assay

PIM Kinase Activity Assay-IMAP Fluorescence Polarization Assay

1. Principle

PIM Is a serine/threonine protein kinase, they can phosphorylate 5-FAM labeled small peptide substrates. Fluorescence polarization is less for non-phosphorylated substrates since that can not bind to the binder (metal binding nanoparticles). On the other hand, fluorescence polarization is more for phosphorylated substrates since that can bind to the binder. The level of 5-FAM labeled small peptide substrates phosphorylation reflects the activities of PIM kinase. By measuring their ability of inhibiting PIM kinase of the compounds of the present invention, their activities of inhibiting PIM kinases can be determined.

2. Instrument

EnVision (PerkinElmer, Waltham, Mass.)

3. Reagents and 384 Well Plates

PIM1 (Millipore Cat. #14-573) (Millipore Corporation, Billerica, Mass.)

PIM2 (Millipore Cat. #14-607) (Millipore Corporation, Billerica, Mass.)

5-FAM labeled peptide (5-FAM-RSRHSSYPAGT, AnaSpec Cat. #63801) (AnaSpec Inc., Fremont Calif.)

IMAP FP Screening Express kit (IMAP FP Screening kit) (Molecular Devices Cat. # R8127) (Molecular Devices, Sunnyvale, Calif.)

IMAP Progressive binding reagent

IMAP Progressive binding buffer A (5×)

IMAP Progressive binding buffer B (5×)

384-well black plate (Corning Cat. #3573) (Corning, Midland Mich.)

4. Assay Buffer

Tris-HCl (pH 7.2): 10 mM

MgCl₂: 10 mM

Triton X-100: 0.01%

DTT: 2 mM

5. Procedure

a) 10 mM compound stock solution is diluted to appropriate concentration with 100% DMSO, then diluted 10 fold to targeted concentration with test butter to keep DMSO concentration at 10%

b) Assay volume 10 ul:

1 ul of compound solution and 4 ul of enzyme (PIM-1 final concentration 0.025 nM, PIM-2 concentration 3 nM) is incubated at 23° C. for 15 min, 2.5 ul ATP (for PIM-1 and PIM-2, the final ATP concentrations are 30 uM and 5 uM respectively) 2.5 ul 5-FAM labeled peptide (final concentration 100 nM) was added to start the reaction. The reaction is run at 23° C. for 60 min. DMSO is used in place of compound stock solution as maximum reference and assay buffer is used in place of enzyme as minimum reference. c) add 30 ul IMAP binding reagent (containing 75% IMAP Buffer A, 25% IMAP Buffer B, 1/600 dilution of beads) to stop the reaction, incubated at room temperature for 60 min d) Measure fluorescence polarization, excitation wavelength: 485 nm, emission wavelength 530 nm. 6. Data process IC₅₀ values were calculated using Graphpad Prism®. PIM kinase assays showed that all 30 compounds in Example 1 through 30 can significantly inhibit the PIM-1, PIM-2 and PIM-3 activities. The IC₅₀ of these compounds range from 0.1 nM to 50 nM. 

I claim:
 1. A compound having a structure of Formula II:

wherein R₁ is a hydrogen, —NHR₄, a halogen, a hydroxyl, an alkyl, a cyano, or a nitro; R₂ is a hydrogen, —NHR₅, a halogen, a hydroxyl, a substituted or unsubstituted alkyl, an alkenyl, an alkynyl, an alkoxyl, a cycloalkyl, an amino, a cyano, or a nitro; R₃ is —NHR₅, a halogen, a hydroxyl, a substituted or unsubstituted alkyl, an alkenyl, an alkynyl, an alkoxyl, a cycloalkyl, an amino, a cyano, or a nitro; R₄ is a hydrogen, —C(═O)—R₅, a substituted or unsubstituted alkyl, a cycloalkyl, a heterocyclyl, an aryl, or a heteroaryl; R₅ is a substituted or unsubstituted alkyl, alkenyl, alkynyl, alkoxyl, cycloalkyl, amino, or substituted amino; R₆ is a substituted or unsubstituted aryl, heteroaryl, cycloalkyl, wherein each substituted R₆ group is substituted with up to four substituents that is a halogen, a cyano, an amino, a C₁₋₄ alkyl, a C₃₋₆ cycloalkyl, an alkoxyl, a nitro, a carboxy, a carbonyl, a carboalkoxy, or an aminocarboxy; R₂₂ is an optionally substituted C₁-C₈ hydrocarbon group or a group having a formula:

wherein each of R₂₃, R₂₄, R₂₅ is independently selected from a H, a halogen, OR₁₅, NR₁₆R₁₇, C(═O)N R₁₈R₁₉, or an optionally substituted C₁-C₈ hydrocarbon group; or R₂₃, R₂₄ and R₂₅, together with atoms to which they are attached, are joined together to form a chain so that the ring to which they are attached is a substituted C₆-C₁₄ membered spiral ring, a bicyclic ring, or a fused ring group; G₁ is CH or N; G₂ is NR₂₈, CHR₂₉, or O; B1 and B2 each independently represents 0, 1, 2, or 3; B3 is 0, 1, or 2; B4 is 0 or 1; each of R₁₆, R₁₇, R₁₈, R₁₉, R₂₆ and R₂₇ is independently selected from a H or an optionally substituted C₁-C₈ hydrocarbon group; R₂₈ is H, an optionally substituted hydrocarbon group, an optionally substituted cyclic hydrocarbon group, an optionally substituted heterocyclic hydrocarbon group, C(═O)R₃₀, C(═O)OR₃₀, or C(═O)NHR₃₀; R₂₉ is OH, NHR₃₀, C(═O)OR₃₀, or C(═O)NHR₃₀; and R₃₀ is H or an optionally substituted C₁-C₈ hydrocarbon group, or a stereoisomer, tautomer, or a pharmaceutically acceptable salt thereof.
 2. The compound according to claim 1, wherein R₂₂ is a substituted or unsubstituted cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, azetidyl, pyrrolidinyl, piperidinyl, azepanyl, oxetyl, tetrahydrofuryl, or tetrahydropyranyl group; R₂₂ group is substituted with up to three substitutents that is an amino, a hydroxy, a methyl, an ethyl, or a methoxy; R₁ is a hydrogen, an amino, or a fluoro; R₂ is a hydrogen, a halogen, or a methyl; R₃ is a halogen; and R₆ is a substituted or unsubstituted phenyl, wherein the substituted phenyl group is substituted with up to three substituents that is a hydrogen, a cyano, a nitro, a halogen, a hydroxyl, an amino, an alkoxy, a substituted amino, an alkyl, or a cycloalkyl.
 3. The compound according to claim 2, wherein R₂₂ is a substituted or unsubstituted cyclohexyl, cycloheptyl, pyrrolidinyl, piperidinyl, or azepanyl group; when R₂₂ is a substituted group, it is substituted with up to three substitutents that is an amino, a hydroxy, or a methyl; R₁ is a hydrogen, an amino, or a fluoro; R₂ is a hydrogen, a halogen, or a methyl; R₃ is a halogen; and R₆ is a substituted or unsubstituted phenyl, and the substituted phenyl group is substituted with up to three substituents that is a hydrogen, a cyano, a nitro group, a halogen, or a hydroxyl.
 4. The compound according to claim 1, wherein R₂₂ is a substituted or unsubstituted cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cycloheptylmethyl, azetidylmethyl, pyrrolidinylmethyl, piperidinylmethyl, azepanylmethyl, oxetylmethyl, tetrahydrofurylmethyl, or tetrahydropyranylmethyl group; R₂₂ group is substituted with up to three substitutents that is an amino, a hydroxy, a methyl, an ethyl, or a methoxy; R₁ is a hydrogen, an amino, or a fluoro; R₂ is a hydrogen, a halogen, or a methyl; R₃ is a halogen; and R₆ is a substituted or unsubstituted phenyl, and the substituted phenyl is substituted with up to three substituents that is a hydrogen, a cyano, a nitro, a halogen, a hydroxyl, an amino, an alkoxy, a substituted amino, an alkyl, or a cycloalkyl.
 5. The compound according to claim 4, wherein R₂₂ is a substituted or unsubstituted cyclohexylmethyl, pyrrolidinylmethyl, piperidinylmethyl, or azepanylmethyl group, the substituted R₂₂ group is substituted with up to three substitutents that is an amino, a hydroxy, or a methyl; R₁ is a hydrogen, an amino, or a fluoro; R₂ is a hydrogen, a halogen, or a methyl; R₃ is a halogen; and R₆ is a substituted or unsubstituted phenyl, and the substituted phenyl is substituted with up to three substituents that is a hydrogen, a cyano, or a halogen.
 6. The compound according to claim 4, wherein R₂₂ is a substituted C₂-C₅ alkyl, the substituted R₂₂ group is substituted at any position on substituent with up to four substitutents that is an amino, an alkylamino, a hydroxy, a halogen, a methyl, an ethyl, a halogenated methyl, or a halogenated ethyl group; R₁ is a hydrogen, an amino, or a fluoro; R₂ is a hydrogen; R₃ is a halogen; and R₆ is a substituted or unsubstituted phenyl, and the substituted phenyl is substituted with up to three substituents that is a hydrogen, a methyl, or a halogen.
 7. The compound according to claim 3, wherein R₁ is a hydrogen or an amino; R₂ is hydrogen; R₃ is a halogen; R₆ is a substituted or unsubstituted phenyl, and the substituted phenyl is substituted with up to three substituents that is a hydrogen or a halogen.
 8. The compound according to claim 5, wherein R₁ is a hydrogen or an amino; R₂ is hydrogen; R₃ is a halogen; R₆ is a substituted or unsubstituted phenyl, and the substituted phenyl is substituted with up to three substituents that is a hydrogen or a halogen.
 9. A compound according to claim 1, wherein the compound is 6-(2,6-difluorophenyl)-5-fluoro-N-(4-(piperidin-4-ylmethoxy)pyrimidin-5-yl)picolinamide; N-(4-(azetidin-3-ylmethoxy)pyrimidin-5-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide; 6-(2,6-difluorophenyl)-5-fluoro-N-(4-(piperidin-4-yloxy)pyrimidin-5-yl)picolinamide; 6-(2,6-difluorophenyl)-5-fluoro-N-(4-(pyrrolidin-3-yloxy)pyrimidin-5-yl)picolinamide; 6-(2,6-difluorophenyl)-5-fluoro-N-(4-(piperidin-3-yloxy)pyrimidin-5-yl)picolinamide; N-(4-(azocan-4-yloxy)pyrimidin-5-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide; 6-(2,6-difluorophenyl)-5-fluoro-N-(4-(piperidin-3-ylmethoxy)pyrimidin-5-yl)picolinamide; 6-(2,6-difluorophenyl)-5-fluoro-N-(4-(pyrrolidin-3-ylmethoxy)pyrimidin-5-yl)picolinamide; N-(4-(azetidin-3-yloxy)pyrimidin-5-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide; N-(4-(((1r,4r)-4-aminocyclohexyl)oxy)pyrimidin-5-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide; N-(4-((3-aminocyclohexyl)oxy)pyrimidin-5-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide; N-(4-(3-aminopropoxy)pyrimidin-5-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide; 6-(2,6-difluorophenyl)-5-fluoro-N-(4-(3-(methylamino)propoxy)pyrimidin-5-yl)picolinamide; 6-(2,6-difluorophenyl)-N-(4-(3-(dimethylamino)propoxy)pyrimidin-5-yl)-5-fluoropicolinamide; N-(4-(4-aminobutoxy)pyrimidin-5-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide; 6-(2,6-difluorophenyl)-5-fluoro-N-(4-(4-(methylamino)butoxy)pyrimidin-5-yl)picolinamide; 6-(2,6-difluorophenyl)-5-fluoro-N-(4-(3-hydroxypropoxy)pyrimidin-5-yl)picolinamide; 6-(2,6-difluorophenyl)-5-fluoro-N-(4-(3-hydroxybutoxy)pyrimidin-5-yl)picolinamide; 6-(2,6-difluorophenyl)-5-fluoro-N-(4-(4-hydroxybutoxy)pyrimidin-5-yl)picolinamide; 6-(2,6-difluorophenyl)-5-fluoro-N-(4-((4-hydroxy-4-methylpentyl)oxy)pyrimidin-5-yl)picolinamide; 6-(2,6-difluorophenyl)-N-(4-(3,4-dihydroxybutoxy)pyrimidin-5-yl)-5-fluoropicolinamide; N-(4-(3-amino-4-hydroxybutoxy)pyrimidin-5-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide; 6-(2,6-difluorophenyl)-5-fluoro-N-(4-((tetrahydro-2H-pyran-4-yl)methoxy)pyrimidin-5-yl)picolinamide; 3-amino-6-(2,6-difluorophenyl)-5-fluoro-N-(4-(piperidin-4-ylmethoxy)pyrimidin-5-yl)picolinamide; 3-amino-6-(2,6-difluorophenyl)-5-fluoro-N-(4-(pyrrolidin-3-yloxy)pyrimidin-5-yl)picolinamide; 3-amino-6-(2,6-difluorophenyl)-5-fluoro-N-(4-(piperidin-4-yloxy)pyrimidin-5-yl)picolinamide; 3-amino-N-(4-(azepan-4-yloxy)pyrimidin-5-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide; 3-amino-N-(4-(((1r,4r)-4-aminocyclohexyl)oxy)pyrimidin-5-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide; 3-amino-6-(2,6-difluorophenyl)-5-fluoro-N-(4-(pyrrolidin-3-ylmethoxy)pyrimidin-5-yl)picolinamideyl)picolinamide; N-(4-((1-amino-3-chloropropan-2-yl)oxy)pyrimidin-5-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide; or N-(4-(3-amino-2-(chloromethyl)propoxy)pyrimidin-5-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide.
 10. A method for using the compound of claim 1, comprising administering to a subject in need of a treatment a therapeutically effective amount of the compound as described in claim 1, wherein the treatment is for treating chronic lymphocytic leukemia, acute lymphoblastic leukemia, acute myeloid leukemia, chronic myelogenous leukemia, non-Hodgkin's lymphoma, multiple myeloma, pancreatic cancers, prostate cancers, liver cancers, gastric cancer, bladder cancer, and inflammatory bowel disease.
 11. A method for using the compound of claim 9, comprising administering to a subject in need of a treatment a therapeutically effective amount of the compound as described in claim 9, wherein the treatment is for treating chronic lymphocytic leukemia, acute lymphoblastic leukemia, acute myeloid leukemia, chronic myelogenous leukemia, non-Hodgkin's lymphoma, multiple myeloma, pancreatic cancers, prostate cancers, liver cancers, gastric cancer, bladder cancer, and inflammatory bowel disease.
 12. A pharmaceutical composition comprising the compound of claim 1 as an active pharmaceutical ingredient and a pharmaceutically acceptable carrier or adjuvant.
 13. A pharmaceutical composition comprising the compound of claim 9 as an active pharmaceutical ingredient and a pharmaceutically acceptable carrier or adjuvant.
 14. A pharmaceutical composition comprising the compound of claim 1 in combination with an additional chemotherapeutic agent. 